Drug Profile
ORM 10921
Alternative Names: ORM-10921Latest Information Update: 10 May 2006
Price :
$50
*
At a glance
- Originator Juvantia Pharma (CEASED); Orion
- Class Neuropsychotherapeutics
- Mechanism of Action Alpha 2c adrenergic receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Major depressive disorder; Schizophrenia
Most Recent Events
- 10 May 2006 Discontinued - Phase-I for Schizophrenia in Finland (unspecified route)
- 10 May 2006 Discontinued - Preclinical for Depression in Finland (unspecified route)
- 15 Nov 2002 Preclinical trials in Depression in Finland (unspecified route)